Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2018-10-28
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ultrasound-guided photodynamic
therapy with porfimer sodium when given together with gemcitabine hydrochloride in treating
patients with locally advanced pancreatic cancer. Photodynamic therapy uses a drug, porfimer
sodium, that becomes active when it is exposed to a certain kind of light. When the drug is
active, cancer cells are killed. Drugs used in chemotherapy, such as gemcitabine
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Giving photodynamic therapy together with
gemcitabine hydrochloride may be effect in patients with pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
John DeWitt
Collaborators:
American Society for Gastrointestinal Endoscopy Pinnacle Biologics Inc.